Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Files An 8-K Other EventsItem 8.01. Other Events.
On July 31, 2018, the board of directors of Titan Pharmaceuticals, Inc. (the “Company”) amended the Company’s Amended and Restated 2015 Equity Incentive Plan (the “Amendment”) to delete provisions relating to potential “gross-up” payments in the event of a change of control of the Company.
The foregoing summary description of the Amendment is qualified in its entirety by reference to the full text of such document attached hereto as Exhibit 10.1, which are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
TITAN PHARMACEUTICALS INC ExhibitEX-10.1 2 tv499798_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDMENT TO TITAN PHARMACEUTICALS,…To view the full exhibit click here
About Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.
